ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 120.47

Change

-2.24 (-1.83)%

Market Cap

USD 26.71B

Volume

3.90M

Yahoo Analyst Target

USD 160.14 (32.93%)

STA Analyst Target

USD 163.37 (35.61%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Alexion Pharmaceuticals Inc is a biopharmaceutical company engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-02-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TIG TiGenix

+0.92 (+2.20%)

USD 253.14B
AMGN Amgen Inc.

-0.05 (-0.03%)

USD 132.26B
GILD Gilead Sciences Inc.

-0.85 (-1.04%)

USD 105.56B
CELG Celgene Corporation

-0.88 (-0.92%)

USD 71.65B
BIIB Biogen Inc.

-7.51 (-2.51%)

USD 61.75B
SHPG Shire plc

-1.24 (-0.92%)

USD 40.67B
VRTX Vertex Pharmaceuticals Incorpo..

-0.22 (-0.14%)

USD 40.65B
REGN Regeneron Pharmaceuticals Inc.

-1.03 (-0.31%)

USD 35.77B
INCY Incyte Corporation

+0.44 (+0.51%)

USD 18.16B
GRFS Grifols S.A.

-0.07 (-0.30%)

USD 15.66B

ETFs Containing ALXN

PBE PowerShares Dynamic Biote.. 4.72 % 0.58 %

+0.15 (+0.29%)

USD 0.25B
BBH VanEck Vectors Biotech ET.. 4.57 % 0.35 %

-0.46 (-0.37%)

USD 0.57B
IBB iShares Nasdaq Biotechnol.. 3.44 % 0.47 %

-0.40 (-0.36%)

USD 9.67B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.74% 49% F 55% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.74% 49% F 54% F
Trailing 12 Months  
Capital Gain -7.61% 46% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.61% 46% F 29% F
Trailing 5 Years  
Capital Gain 40.07% 56% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.07% 56% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 8.26% 53% F 50% F
Dividend Return 8.26% 52% F 47% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.66% 72% C- 39% F
Risk Adjusted Return 24.55% 60% D- 38% F
Market Capitalization 26.24B 98% A+ 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.80 3% F 9% F
Price/Book Ratio 3.03 57% F 37% F
Price / Cash Flow Ratio 5.71 7% F 19% F
Price/Free Cash Flow Ratio 31.21 5% F 16% F
Management Effectiveness  
Return on Equity 5.72% 82% B- 55% F
Return on Invested Capital 5.53% 85% B 55% F
Return on Assets 3.76% 91% A- 75% C
Debt to Equity Ratio 37.00% 37% F 54% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

ALXN:NGS-Alexion Pharmaceuticals Inc.

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 120.47

Change

-2.24 (-1.83)%

Market Cap

USD 26.71B

Volume

3.90M

Yahoo Analyst Target

USD 160.14 (32.93%)

STA Analyst Target

USD 163.37 (35.61%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-02-16